cocaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
local anaesthetics	723	50-36-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cocaine cocain benzoylmethylecgonine cocaine hydrochloride cocaine HCl	An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Molecular weight: 303.36 Formula: C17H21NO4 CLOGP: 2.57 LIPINSKI: 0 HAC: 5 HDO: 0 TPSA: 55.84 ALOGS: -1.78 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cocaine
cocain
benzoylmethylecgonine
cocaine hydrochloride
cocaine HCl

An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.

Molecular weight: 303.36
Formula: C17H21NO4
CLOGP: 2.57
LIPINSKI: 0
HAC: 5
HDO: 0
TPSA: 55.84
ALOGS: -1.78
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1.60 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.95 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	57 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	32 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.12 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.76 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1860	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	3772.94	80.52	947	5245	71571	63411259
Toxicity to various agents	1709.94	80.52	697	5495	246553	63236277
Completed suicide	854.13	80.52	368	5824	145305	63337525
Cardio-respiratory arrest	692	80.52	248	5944	59711	63423119
Respiratory arrest	621.90	80.52	197	5995	32448	63450382
Cardiac arrest	508.20	80.52	224	5968	92321	63390509
Death	354.86	80.52	291	5901	374090	63108740
Intentional product misuse	275.22	80.52	129	6063	60788	63422042
Substance abuse	256.38	80.52	65	6127	4742	63478088
Poisoning deliberate	222.58	80.52	70	6122	11148	63471682
Drug dependence	221.59	80.52	85	6107	24398	63458432
Miosis	189.00	80.52	56	6136	7297	63475533
Poisoning	154.77	80.52	56	6136	13644	63469186
Overdose	146.24	80.52	107	6085	114971	63367859
Coma	100.60	80.52	68	6124	64296	63418534
Bradypnoea	95.41	80.52	28	6164	3522	63479308
Opiates positive	93.12	80.52	18	6174	368	63482462
Suicide attempt	89.60	80.52	62	6130	60856	63421974
Accidental overdose	88.78	80.52	44	6148	23265	63459565
Asphyxia	87.89	80.52	30	6162	6151	63476679
Incorrect route of product administration	84.81	80.52	45	6147	27407	63455423
Mydriasis	81.93	80.52	34	6158	11922	63470908

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	8289.54	50.96	2572	12211	96524	34845624
Toxicity to various agents	2439.91	50.96	1319	13464	199043	34743105
Intentional product misuse	767.38	50.96	377	14406	45234	34896914
Drug dependence	726.31	50.96	300	14483	23917	34918231
Coma	575.43	50.96	311	14472	45367	34896781
Cardio-respiratory arrest	556.94	50.96	325	14458	54948	34887200
Poisoning	475.93	50.96	183	14600	12043	34930105
Respiratory arrest	468.41	50.96	231	14552	27812	34914336
Miosis	441.19	50.96	162	14621	9373	34932775
Substance abuse	433.48	50.96	151	14632	7490	34934658
Asphyxia	391.26	50.96	136	14647	6699	34935449
Completed suicide	361.30	50.96	312	14471	97856	34844292
Cardiac arrest	287.41	50.96	272	14511	95887	34846261
Overdose	248.31	50.96	245	14538	90814	34851334
Substance use disorder	226.91	50.96	55	14728	724	34941424
Agitation	217.93	50.96	186	14597	57213	34884935
Mydriasis	194.20	50.96	83	14700	7154	34934994
Drug use disorder	189.26	50.96	70	14713	4121	34938027
Poisoning deliberate	174.97	50.96	79	14704	7765	34934383
Depressed level of consciousness	150.70	50.96	133	14650	42708	34899440
Bradypnoea	149.21	50.96	53	14730	2776	34939372
Drug ineffective	148.93	50.96	12	14771	456739	34485409
Diarrhoea	143.28	50.96	5	14778	389907	34552241
Pulmonary oedema	135.08	50.96	131	14652	47398	34894750
Death	131.74	50.96	417	14366	397632	34544516
Altered state of consciousness	116.12	50.96	88	14695	22805	34919343
Incorrect route of product administration	114.99	50.96	74	14709	14771	34927377
Alcohol abuse	113.42	50.96	50	14733	4640	34937508
Fatigue	112.08	50.96	13	14770	370640	34571508
Withdrawal syndrome	111.35	50.96	68	14715	12387	34929761
Pneumonia	108.94	50.96	13	14770	362614	34579534
Respiratory depression	108.92	50.96	74	14709	16171	34925977
Postmortem blood drug level abnormal	107.15	50.96	25	14758	276	34941872
Aggression	95.23	50.96	99	14684	38865	34903283
Pyrexia	92.78	50.96	15	14768	332998	34609150
Asthenia	90.43	50.96	3	14780	245248	34696900
Drug detoxification	88.25	50.96	21	14762	254	34941894
Nausea	84.82	50.96	20	14763	339888	34602260
Rhabdomyolysis	81.69	50.96	121	14662	68042	34874106
Prescription drug used without a prescription	79.29	50.96	31	14752	2123	34940025
Toxicologic test abnormal	78.10	50.96	22	14761	534	34941614
Rash	77.84	50.96	4	14779	222748	34719400
Opiates positive	77.15	50.96	22	14761	559	34941589
Dyspnoea	68.82	50.96	37	14746	376745	34565403
Dizziness	67.60	50.96	7	14776	218514	34723634
Suicidal behaviour	67.55	50.96	25	14758	1472	34940676
Anaemia	66.05	50.96	10	14773	233325	34708823
Cluster headache	64.36	50.96	19	14764	547	34941601
Somnolence	62.33	50.96	142	14641	110974	34831174
Amphetamines positive	61.28	50.96	15	14768	206	34941942
Off label use	60.91	50.96	53	14730	419471	34522677
Mixed anxiety and depressive disorder	60.40	50.96	13	14770	96	34942052
Tachycardia	57.47	50.96	117	14666	84655	34857493
Drug abuser	55.44	50.96	29	14754	3925	34938223
Intentional overdose	54.41	50.96	79	14704	43595	34898553
Weight decreased	53.60	50.96	6	14777	176295	34765853
Intentional product use issue	53.53	50.96	93	14690	59723	34882425

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	12023.23	55.11	3411	16620	159280	79565077
Toxicity to various agents	3843.69	55.11	1923	18108	419617	79304740
Cardio-respiratory arrest	1176.25	55.11	563	19468	107947	79616410
Intentional product misuse	1052.95	55.11	501	19530	94664	79629693
Respiratory arrest	1020.42	55.11	422	19609	57128	79667229
Completed suicide	1008.34	55.11	674	19357	245093	79479264
Drug dependence	913.40	55.11	354	19677	40415	79683942
Cardiac arrest	733.27	55.11	484	19547	171612	79552745
Poisoning	650.47	55.11	243	19788	25029	79699328
Miosis	644.55	55.11	214	19817	15575	79708782
Coma	637.66	55.11	365	19666	100284	79624073
Substance abuse	553.68	55.11	173	19858	10353	79714004
Death	500.17	55.11	659	19372	565855	79158502
Asphyxia	458.92	55.11	154	19877	11566	79712791
Poisoning deliberate	366.87	55.11	148	19883	18680	79705677
Overdose	345.03	55.11	319	19712	183887	79540470
Substance use disorder	289.42	55.11	63	19968	875	79723482
Agitation	284.03	55.11	220	19811	99495	79624862
Mydriasis	280.61	55.11	120	19911	17523	79706834
Bradypnoea	238.73	55.11	80	19951	5972	79718385
Drug use disorder	236.36	55.11	87	19944	8564	79715793
Depressed level of consciousness	213.58	55.11	184	19847	96468	79627889
Altered state of consciousness	204.80	55.11	131	19900	43691	79680666
Drug ineffective	198.35	55.11	21	20010	1080892	78643465
Diarrhoea	191.15	55.11	7	20024	880482	78843875
Fatigue	175.84	55.11	16	20015	929711	78794646
Incorrect route of product administration	174.66	55.11	109	19922	34820	79689537
Respiratory depression	163.33	55.11	96	19935	27534	79696823
Opiates positive	162.95	55.11	40	19991	964	79723393
Pulmonary oedema	147.98	55.11	144	19887	88110	79636247
Alcohol abuse	146.73	55.11	54	19977	5309	79719048
Withdrawal syndrome	144.94	55.11	88	19943	26766	79697591
Postmortem blood drug level abnormal	136.89	55.11	32	19999	622	79723735
Nausea	133.37	55.11	38	19993	957158	78767199
Suicide attempt	131.01	55.11	131	19900	82801	79641556
Aggression	126.88	55.11	104	19927	50854	79673503
Drug detoxification	123.95	55.11	27	20004	376	79723981
Rash	123.93	55.11	5	20026	578353	79146004
Dyspnoea	123.12	55.11	32	19999	856993	78867364
Pain	123	55.11	16	20015	703786	79020571
Toxicologic test abnormal	122.78	55.11	34	19997	1326	79723031
Amphetamines positive	122.63	55.11	26	20005	316	79724041
Rhabdomyolysis	119.07	55.11	138	19893	102993	79621364
Intentional overdose	117.69	55.11	139	19892	105821	79618536
Asthenia	104.52	55.11	6	20025	511683	79212674
Prescription drug used without a prescription	103.94	55.11	39	19992	4046	79720311
Accidental overdose	103.21	55.11	83	19948	39498	79684859
Pneumonia	99.93	55.11	22	20009	660224	79064133
Pyrexia	98.02	55.11	25	20006	678684	79045673
Somnolence	94.05	55.11	194	19837	238787	79485570
Dizziness	89.44	55.11	13	20018	526428	79197929
Cough	79.06	55.11	3	20028	366786	79357571
Anaemia	75.53	55.11	11	20020	445004	79279353
Suicidal ideation	74.74	55.11	94	19937	76246	79648111
Postmortem blood drug level	72.69	55.11	17	20014	331	79724026
Tachycardia	70.69	55.11	145	19886	177623	79546734
Condition aggravated	69.37	55.11	20	20011	501104	79223253
Off label use	69.01	55.11	76	19955	907139	78817218
Drug abuser	67.24	55.11	32	19999	5981	79718376
Pruritus	66.39	55.11	10	20021	394638	79329719
Headache	65.33	55.11	42	19989	653730	79070627
Cluster headache	63.53	55.11	19	20012	977	79723380
Hypothermia	62.06	55.11	49	19982	22697	79701660
Unresponsive to stimuli	61.58	55.11	73	19958	55715	79668642
Suicidal behaviour	61.40	55.11	25	20006	3222	79721135
Accidental death	61.06	55.11	27	20004	4264	79720093
Weight decreased	57.49	55.11	10	20021	355188	79369169
Decreased appetite	56.85	55.11	9	20022	342409	79381948

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sudden infant death syndrome	17.98	15.80	3	3	53	89733

Pharmacologic Action:

Source	Code	Description
ATC	N01BC01	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, LOCAL Esters of benzoic acid
ATC	R02AD03	RESPIRATORY SYSTEM THROAT PREPARATIONS THROAT PREPARATIONS Anesthetics, local
ATC	S01HA01	SENSORY ORGANS OPHTHALMOLOGICALS LOCAL ANESTHETICS Local anesthetics
ATC	S02DA02	SENSORY ORGANS OTOLOGICALS OTHER OTOLOGICALS Analgesics and anesthetics
MeSH PA	D000777	Anesthetics
MeSH PA	D000779	Anesthetics, Local
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D014662	Vasoconstrictor Agents
CHEBI has role	CHEBI:35337	analeptic
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:36333	local anesthetics
CHEBI has role	CHEBI:38633	sodium channel blockers
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:51039	dopamine reuptake inhibitor
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:78298	environmental contaminants
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Local anesthesia	indication	386761002
Conduction disorder of the heart	contraindication	44808001
Epilepsy	contraindication	84757009	DOID:1826
Thyrotoxicosis	contraindication	90739004	DOID:7997
Disorder of mucous membrane	contraindication	95351003
Acute disease of cardiovascular system	contraindication	128487001
Breastfeeding (mother)	contraindication	413712001
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.27	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10016407	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10149843	Feb. 7, 2037	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10149843	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10413505	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10420760	Feb. 7, 2037	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10857095	Feb. 7, 2037	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10894012	Feb. 7, 2037	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10933060	Feb. 7, 2037	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10973811	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	10987347	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	9867815	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	9867815	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
4%	GOPRELTO	GENUS LIFESCIENCES	N209963	Dec. 14, 2017	RX	SOLUTION	NASAL	9867815	Feb. 7, 2037	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
4%	NUMBRINO	CODY LABS INC	N209575	Jan. 10, 2020	RX	SOLUTION	NASAL	Jan. 10, 2023	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	INHIBITOR	Ki	7.50	CHEMBL	IUPHAR
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.05	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.14	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.92	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.57	WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	5.68	WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	5.67	WOMBAT-PK
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	5.47	WOMBAT-PK
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	5.71	WOMBAT-PK
Sodium- and chloride-dependent GABA transporter 1	Transporter	P30531	SC6A1_HUMAN		IC50	5.50	WOMBAT-PK
Sodium channel protein type 11 subunit alpha	Ion channel	Q9UI33	SCNBA_HUMAN				WOMBAT-PK
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		IC50	5.10	WOMBAT-PK
Cocaine- and amphetamine-regulated transcript protein	Transcription factor	Q16568	CART_HUMAN				WOMBAT-PK
Serotonin 3 receptor (5HT3)	Ion channel	O95264 P46098	5HT3B_HUMAN 5HT3A_HUMAN	ANTAGONIST	Ki	4.80	IUPHAR
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	4.31	CHEMBL
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN				WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	4.21	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	7.35	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	7.49	CHEMBL
Transporter	Transporter		Q9WTR4_RAT		Ki	6.97	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_MOUSE		IC50	6.70	CHEMBL
Transporter	Transporter		Q63380_RAT		Ki	5.50	CHEMBL
Dopamine transporter	Transporter		SC6A3_BOVIN		IC50	7.19	CHEMBL
Dopamine transporter	Transporter		SC6A3_MACFA		IC50	7.02	CHEMBL

External reference:

ID	Source
4019690	VUID
N0000147782	NUI
D00110	KEGG_DRUG
53-21-4	SECONDARY_CAS_RN
2653	RXNORM
4017521	VANDF
4019690	VANDF
C0009170	UMLSCUI
CHEBI:27958	CHEBI
CCA	PDB_CHEM_ID
CHEMBL370805	ChEMBL_ID
CHEMBL120901	ChEMBL_ID
DB00907	DRUGBANK_ID
CHEMBL529437	ChEMBL_ID
D003042	MESH_DESCRIPTOR_UI
446220	PUBCHEM_CID
2286	IUPHAR_LIGAND_ID
I5Y540LHVR	UNII
437	MMSL
4488	MMSL
d03878	MMSL
001369	NDDF
001370	NDDF
14816004	SNOMEDCT_US
387085005	SNOMEDCT_US
74273006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
NUMBRINO	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1961	SOLUTION	40 mg	NASAL	NDA	30 sections
NUMBRINO	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1961	SOLUTION	40 mg	NASAL	NDA	30 sections
cocaine hydrochloride nasal	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1971	SOLUTION	40 mg	TOPICAL	NDA authorized generic	30 sections
cocaine hydrochloride nasal	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1971	SOLUTION	40 mg	TOPICAL	NDA authorized generic	30 sections
cocaine hydrochloride nasal	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1971	SOLUTION	40 mg	TOPICAL	NDA authorized generic	30 sections
GOPRELTO	HUMAN PRESCRIPTION DRUG LABEL	1	64950-359	SOLUTION	40 mg	NASAL	NDA	35 sections
GOPRELTO	HUMAN PRESCRIPTION DRUG LABEL	1	64950-359	SOLUTION	40 mg	NASAL	NDA	35 sections
cocaine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	64950-362	SOLUTION	40 mg	NASAL	NDA AUTHORIZED GENERIC	35 sections
cocaine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	64950-362	SOLUTION	40 mg	NASAL	NDA AUTHORIZED GENERIC	35 sections